India, Jan. 27 -- Caplin Steriles Ltd, a subsidiary of Caplin Point Laboratories Ltd, has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Methylprednisolone Acetate Injectable Suspension USP in 40 mg/mL and 80 mg/mL single-dose vials.
The approved product is a generic therapeutic equivalent of Pfizer Inc.'s reference listed drug DEPO-MEDROL. Methylprednisolone Acetate Injectable Suspension is used as an anti-inflammatory treatment across a wide range of conditions, including allergic, dermatologic, endocrine, gastrointestinal, hematologic, ophthalmic, respiratory and rheumatic disorders.
According to IQVIA (IMS Health) data, the Methylprednisolone Acet...